Evolent Health, Inc. (EVH)
USD 10.69
(7.44%)
USD 10.69
(7.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.78 Million USD | 530.18% |
| 2022 | 43.74 Million USD | -91.85% |
| 2021 | 55.66 Million USD | 282.68% |
| 2020 | -241.38 Million USD | 136.04% |
| 2019 | -245.94 Million USD | -692.95% |
| 2018 | -4.15 Million USD | 79.36% |
| 2017 | -40.4 Million USD | -141.31% |
| 2016 | -220.3 Million USD | 121.52% |
| 2015 | -31.5 Million USD | -1682.22% |
| 2014 | -25.24 Million USD | 61.86% |
| 2013 | -20.34 Million USD | -239.36% |
| 2012 | -19.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 40.44 Million USD | 115.29% |
| 2024 Q1 | 35.33 Million USD | 401.67% |
| 2023 Q2 | 27.54 Million USD | 173.58% |
| 2023 Q4 | 26.73 Million USD | -9.52% |
| 2023 FY | - USD | 530.18% |
| 2023 Q3 | 29.54 Million USD | 7.26% |
| 2023 Q1 | -37.43 Million USD | -2080.08% |
| 2022 FY | - USD | -91.85% |
| 2022 Q2 | 13.75 Million USD | -28.67% |
| 2022 Q3 | -23.95 Million USD | -274.18% |
| 2022 Q1 | 19.27 Million USD | -52.29% |
| 2022 Q4 | -1.71 Million USD | 92.83% |
| 2021 Q3 | 8.19 Million USD | -32.68% |
| 2021 Q4 | 40.4 Million USD | 393.07% |
| 2021 Q1 | 29.66 Million USD | 291.26% |
| 2021 Q2 | 12.17 Million USD | -58.97% |
| 2021 FY | - USD | 282.68% |
| 2020 Q3 | -8.19 Million USD | -126.87% |
| 2020 Q2 | 30.5 Million USD | 584.39% |
| 2020 FY | - USD | 136.04% |
| 2020 Q4 | 7.58 Million USD | 192.53% |
| 2020 Q1 | -6.29 Million USD | -23.23% |
| 2019 FY | - USD | -692.95% |
| 2019 Q1 | -31.21 Million USD | -1067.86% |
| 2019 Q4 | -5.11 Million USD | 36.51% |
| 2019 Q3 | -8.04 Million USD | 61.83% |
| 2019 Q2 | -21.09 Million USD | 32.44% |
| 2018 FY | - USD | 79.36% |
| 2018 Q4 | -2.67 Million USD | -139.73% |
| 2018 Q2 | -855 Thousand USD | 76.34% |
| 2018 Q1 | -3.61 Million USD | 42.94% |
| 2018 Q3 | -1.11 Million USD | -30.41% |
| 2017 FY | - USD | -141.31% |
| 2017 Q4 | -6.33 Million USD | -3.03% |
| 2017 Q3 | -6.14 Million USD | 50.22% |
| 2017 Q2 | -12.34 Million USD | 18.64% |
| 2017 Q1 | -15.17 Million USD | 51.9% |
| 2016 Q1 | 149.39 Million USD | 1450.5% |
| 2016 FY | - USD | 121.52% |
| 2016 Q4 | -31.55 Million USD | -160.89% |
| 2016 Q3 | -12.09 Million USD | -34.11% |
| 2016 Q2 | -9.01 Million USD | -106.04% |
| 2015 FY | - USD | -1682.22% |
| 2015 Q2 | -424.68 Million USD | -2277.34% |
| 2015 Q3 | -14.19 Million USD | 96.66% |
| 2015 Q4 | -11.06 Million USD | 22.04% |
| 2015 Q1 | -17.86 Million USD | -66.98% |
| 2014 Q3 | -3.16 Million USD | 51.98% |
| 2014 Q2 | -6.59 Million USD | 39.98% |
| 2014 Q4 | -10.69 Million USD | -237.8% |
| 2014 Q1 | -10.98 Million USD | -1216.67% |
| 2014 FY | - USD | 61.86% |
| 2013 FY | - USD | -239.36% |
| 2013 Q4 | 984 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Well Corporation | -225.99 Million USD | 89.033% |
| Doximity, Inc. | 195.46 Million USD | 112.68% |
| MultiPlan Corporation | 651.93 Million USD | 103.802% |
| Phreesia, Inc. | -102.94 Million USD | 75.924% |
| Teladoc Health, Inc. | 153.99 Million USD | 116.094% |
| Veeva Systems Inc. | 429.33 Million USD | 105.773% |